Atriva Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
10
Active:4
Completed:2
Trial Phases
2 Phases
Phase 1:6
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (60.0%)Phase 2
4 (40.0%)Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- 🇩🇪
Atriva study site, Neu-Ulm, Germany
Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 133
- Registration Number
- NCT04776044
- Locations
- 🇩🇪
Atriva study site 49006, Augsburg, Germany
🇩🇪Atriva study site 49001, Berlin, Germany
🇩🇪Atriva study site 49013, Berlin, Germany
Phase 1 Study of ATR-002
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: ATR-002 MEK InhibitorDrug: Placebo oral tablet
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04385420
- Locations
- 🇧🇪
SGS Life Sciences, Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium
News
No news found